Your Shopping Cart
By using this site you agree to our use of cookies. Please refer to our privacy policy for more information. Close
Hello. Sign In
Your Account

Log In to ComplianceOnline
Welcome back! Please log in below to continue.
0
Cart
Toll Free:
+1-888-717-2436
+1-888-717-2436
Industries
- Banking & Financial Services
- BANKING & FINANCIAL SERVICES
- Banks and Credit Unions
- Financial Services and Trading
- Insurance
- Accounting and Taxation
- Life Sciences
- Hitech, Aero & Manufacturing
- HITECH, AERO & MANUFACTURING
- Quality & Safety
- Standards and Methodology
- Energy & Utilities
- ENERGY & UTILITIES
- IT Security
- Reliability (NERC / FERC)
- Quality and Safety
- Risk Management
- CPG & Retail
- CPG & RETAIL
- Retail Audit
- Quality & Safety
- Social Compliance
- Healthcare
- Food & Dietary Supplements
- Cross Industry Functions
Webinars
By Industries
Seminars
Quality Control Laboratory Compliance - cGMPs and GLPs
Process Validation Guidance Requirements (FDA and EU Annex 15: ...
FDA Recalls - Before You Start, and After You Finish
Biostatistics for the Non-Statistician
Data Integrity: FDA/EU Requirements and Implementation
Managing Domestic and Foreign FDA Inspections and the ...
Recordkeeping and Documentation in a GLP Laboratory ...
Reduce costs for compliance with data integrity: 21 CFR Part 11 ...
Change Control Best Practices - Avoiding Unintended ...
Technical Writing for Pharma, Biotech and Medical Devices
Standards
Aerospace
Agriculture and Farm Machinery
Automotive, Aircraft & Marine technology
Banking, Corp. finance & Sox
Biotech & Pharmaceutical Standards
Chemical technology
Civil engineering and construction
Computer Hardware
Electrical Engineering
Electronic Equipment
ANSI
Audit Net
BIN
BPA
Business Basics
Complianceonline
IT Governance
LabCompliance
Quality-Control-Plan
RCGLOBAL
SHOQ Quality Assurance Manuals
SEPT
Home
› Best Practices
Viral Safety Evaluation
- Date: February 18, 2011
- Source: Admin
Standards in controlling viral contamination of biotechnology products:
- Selection and testing of starting materials (cell banks, raw materials etc.)
- Product testing at various stages of production
- Assessing the capacity of the production processes to clear infectious viruses and incorporating viral inactivation and removal steps.
Strategies to evaluate risk of viral contamination and removal of virus:
- Thorough characterization/screening of cell substrate starting material in order to identify which, if any, viral contaminants are present
- Assessment of risk by determination of the human tropism of the contaminants
- Establishment of an appropriate program of testing for adventitious viruses in unprocessed bulk
- Careful design of viral clearance studies using different methods of virus inactivation or removal in the same production process in order to achieve maximum viral clearance
- Performance of studies which assess virus inactivation and removal
Virus Safety Principles
ICH: Q5A or CPMP/ICH/295/95: Note for guidance on quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin.
- Cell line qualification: testing of viruses
- Testing for viruses in unprocessed bulk
- Evaluation and characterization of viral clearance studies
Regulatory guidelines
ICH Q5A: 1. Viral Safety Evaluation of Biotechnology Products Derived from Cell lines of Human or Animal origin 1, (1997) |
· Requires manufacturer to demonstrate the capability of the manufacturing process to remove or inactivate known contaminants. |
FDA: 1. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use 2 (1997) 2. Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals 3 (1993) |
· Similar guidelines as ICH Q5A guideline
· Further viral safety evaluation methods |
EMEA - CPMP guidelines: The 2008 EMEA – CHMP guidelines on viral validation 1. Guideline on Virus Safety Evaluation of Biotechnological Investigational Medicinal Products 4 1996 EMEA - CPMP guidelines 2. Note for Guidance on Virus Validation Studies: The Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses 5 3. CPMP’s Note for Guidance on Plasma Derived Medicinal Products 6 provides detailed recommendations for the manufacturers of biopharmaceutical products to follow when performing viral validations. |
· Recommendations for manufacturers to follow when performing viral validations · Set specific values for virus clearance levels that had to be attained
|
EU Clinical Trials Directive 2001/20/EC 7
The International Standard ISO 22442-3: Medical devices utilizing animal tissues and their derivatives – Part 3: Validation of the elimination and/or inactivation of viruses and transmissible spongiform encephalopathy (TSE) agents 8 |
· All EU Member States now require submission of an Investigational Medicinal Product Dossier (IMPD) starting at phase 1
· Requirements on viral clearance for the medical devices
|
Guidance
FDA Q5A Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin |
Describes approaches risk evaluation of viral contamination and potential of the production process to remove viruses. |
Source
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073454.pdf
http://www.microbac.com/technical_articles/news_detail.php?news_ID=64
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM129101.pdf
Compliance Trainings

Pregnancy in the Workplace: Strategies to Protect Your Organization from Pregnancy Discrimination Claims
By - Christopher W. Olmsted
On Demand Access Anytime
By - Christopher W. Olmsted
On Demand Access Anytime

How to Vet an IRB: Expose and Fix Problems Before They Threaten Your Trial
By - Madhavi Diwanji
On Demand Access Anytime
By - Madhavi Diwanji
On Demand Access Anytime

Compliance Standards
Best Sellers
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
-
By: Miles HutchinsonAdd to CartPrice: $249
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
-
San Francisco, CA | Aug 6-7, 2020
-
Virtual Seminar | Jul 16-17, 2020
-
Virtual Seminar | Jun 18-19, 2020
-
Los Angeles, CA | Aug 20-21, 2020
-
Virtual Seminar | Jul 16-17, 2020
-
Virtual Seminar | Jun 25-26, 2020
-
Virtual Seminar | Jun 10, 2020
-
Virtual Seminar | Jun 3-4, 2020
-
Virtual Seminar | Jul 6-7, 2020
-
San Francisco, CA | Oct 22-23, 2020
-
Virtual Seminar | Jul 9-10, 2020
-
Virtual Seminar | Jun 3-4, 2020
-
Virtual Seminar | June 3-4, 2020
-
Miami, FL | Jul 29-31, 2020
-
Virtual Seminar | Jun 17, 2020
-
Provider: ANSIAdd to CartPrice: $142
- Add to Cart
- Add to Cart
- Add to Cart
-
Provider: ANSIAdd to CartPrice: $120
-
Provider: ANSIAdd to CartPrice: $250
-
Provider: SEPTAdd to CartPrice: $299
- Add to Cart
-
Provider: Quality-Control-PlanAdd to CartPrice: $37
- Add to Cart
-
Provider: At-PQCAdd to CartPrice: $397
- Add to Cart
- Add to Cart
- Add to Cart
- Add to Cart
You Recently Viewed
